EEG alpha power and delirium in the postanaesthesia care unit in older adults: the AlphaMax trial part 1 - effect of desflurane and fentanyl titration during maintenance.

Gaskell, Amy L; Banerji, Antara; Pullon, Rebecca M; Termaat, Jonathan; García, Paul S; Sleigh, Jamie W · Br J Anaesth · 2026

rct · Level II

Where this comes from

Abstract

Frontal EEG alpha oscillations might reflect an ideal state of general anaesthesia with adequate antinociception. Low alpha power has been associated with a vulnerable brain phenotype at greater risk of postoperative delirium. This arm of the AlphaMax randomised trial aimed to determine if alpha oscillations could be maximised by EEG-guided titration of anaesthesia, and if this might reduce delirium in the postanaesthesia care unit (PACU). Male and female patients, aged ≥60 yr, were randomised to EEG-guided dose titration (targeting oscillatory alpha power) or routine care. Both groups received a standardised desflurane-fentanyl-based anaesthetic technique avoiding burst suppression. PACU delirium was assessed by blinded observers. For feasibility reasons, we reduced the sample size and were underpowered for PACU delirium. A total of 200 patients aged 73 (SD 7) yr were included. The titration group received more fentanyl (median [interquartile range] 650 [500-850] μg vs 500 [350-600] μg, P<0.0001) and less desflurane (maintenance end-tidal concentration mean [SD] 3.9 [0.7] vol% vs 4.4 [0.8%], vol% P<0.0001) than the control group. Oscillatory alpha power was greater in the titration group early after surgical incision (+0.8 dB, P=0.008), but this effect was not sustained as surgery progressed. Titration resulted in absent desflurane-alpha correlation in the intervention group (r=-0.020, 95% confidence interval -0.155 to 0.115) and a negative association in the control group (r=-0.228, 95% confidence interval -0.396 to -0.059). The incidence of PACU delirium was similar between groups (37% vs 33%, P=0.553). EEG-guided titration of fentanyl and desflurane anaesthesia had a limited enhancing effect on oscillatory alpha power with no appreciable difference in clinical outcomes. Australian and New Zealand Clinical Trial Registry (ID: 12617001354370).

Medical subject headings